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Chapter I 
 
 
         1.1 Introduction 
   Colon cancer is tumor of the large intestine, the lower part of digestive system; rectal 
cancer affects the last several inches of the colon. Together, they are often referred to as 
colorectal cancers (CRC). It represents the second highest cause of cancer-related death 
in the Western countries. The frequency of colorectal cancer varies around the world. It 
is common in the Western world, where the people have adopted western diets and it is 
rare in Asia and Africa. CRC is growths arising from the inner wall of the large 
intestine, beginning as small, noncancerous (benign) clumps of cells called 
adenomatous polyps (Figure 1). 
 
 
 
 
 
 
 
 
               Figure 1. Schematic representation of early colon cancer stages 
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• age 50 or older; 
• a family history of colon or rectal cancer; 
• a history of polyps in the colon; 
• hereditary condition, such as familial adenomatous polyposis and hereditary non 
polyposis colon cancer (HNPCC; Lynch Syndrome); 
• a history of ulcerative colitis (ulcers in the lining of the large intestine) or Chron 
disease. 
 
 
   Colorectal cancer results from the accumulation of diverse structural and functional 
genomic aberrations, which develop over an extend time interval.Genetic alterations are 
generally random, but mutations may occur in a preferential order, correlating with 
histologic progression from the pre-invasive adenoma to carcinoma. 
   De-regulation of Adenomatous Polyposis Coli (APC) gene represents one of the 
earliest alterations in the multistep process of colon carcinogenesis, proposed by Fearon 
and Vogelstein in 1990, causing  early adenoma formation (1). In addition, mutations in 
BRAF and KRAS genes induce the intermediate adenoma stage, while mutations in 
Smad4 (Small Mother against DPP homolog 4), CDC4 (Cell Division Cycle 4) , DCC 
(Delected in Colorectal Cancer) or MMR (mismatch repair) deficiency characterize late 
adenoma. Finally, p53 mutations degenerate in invasive cancer. Lastly, unknown factors 
lead to metastatic cancer (2,3). (Figure 2) 
 
 
 
 
 
 3 
 
Normal epithelium
hyperplasia
Intermediate 
adenoma
Early adenoma
cancer
Late adenoma
Loss o mutation
APC
hyperproliferation
K-Ras
B-Raf
SMAD4
DCC
Loss o mutation
p53
Multistep process
Anatomo-pathological evolution
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Anatomo-molecular correlation in colorectal cancer pathogenesis 
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1.2 Hystology and classification of colorectal cancer 
   Tumor histology will categorize the cancer into a particular type. It can be either 
adenocarcinoma (95 percent of all colon cancers), epidermoid carcinomas (0.52 to 0.29 
percent) or other rarer types of cancer (e.g. sarcomas). The most frequent histological 
type of colon cancer is represented by adenocarcinoma which accounts for 90-95% 
among all large intestine tumors.  
   Colloidal or mucinous adenocarcinoma  represent only 17% of colon cancer and  
these variants of adenocarcinoma are characterized by large amounts 
of extracellular mucin retained within the tumor. Furthermore, it is undifferentiated, 
thus it correlates with a worse prognosis. 
   Histological examination of the tumor also determines the grade level of the cancer.   
The prognosis in patients with colorectal cancer depends strongly on the degree of local 
tissue invasion, infiltration of adjacent organs and presence of metastases to lymph 
nodes or other organs. The two most common methods are the TNM classification and 
Dukes staging, which correlate closely with the profile prognosis and survival at 5 
years. The Duke’s classification, proposed in 1932, is based on tissue infiltration, lymph 
node involvement and the presence of distant metastases. In particular, a Dukes A colon 
cancer is confined to the muscular lining of the intestinal wall. A Dukes B cancer is one 
in which the cancer has grown beyond the muscular layer of the bowel wall, and a 
Dukes C colon cancer has spread to involve the lymph nodes. 
   The most recent TNM classification, gives more attention to the degree of tissue 
infiltration, discriminating among the invasion of only the mucosa, 
muscle layer or serosa. Staging of colon cancers is useful in predicting the probability of 
the cancer recurring after surgical removal. It also helps in determining whether 
chemotherapy may be helpful in preventing or decreasing the likelihood of a cancer 
recurrence. Stage I cancers have a survival rate of 85-90 percent. Stage II tumors have 
survival rates ranging from 55 to 80 percent. A stage III colon cancer has about a 40 
percent chance of cure and a patient with a stage IV tumor has only a 5 percent chance 
of a cure (2,4) (Table 1). 
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Tabella 1-summary classification of colorectal cancer
5%Distant metastasesIVTx Nx M1D
35-65%Involvement of 
regional lymph nodes
IIITx N1 M0C
55-80%It extends to the serosaIIT3 N0 M0B2
85%It extends to the 
muscular layer
IT2 N0 M0B1
>90%It affects the mucosa 
and submucosa
IT1 N0 M0A
5 years survivalAnatomopathological
description
Numerical
classification
TNMDukes
 
 
 
 
 
 
 
   Another important parameter is the degree of aggressiveness of the tumor or its 
cellular differentiation degree (G) raging from 1 to 3 : 
• G1, well-differentiated carcinoma (25%) 
• G2, moderately differentiated carcinoma (60%) 
• G3, poorly differentiated carcinoma (15%) 
 
   The grading affects the prognosis that worsens progressively from G1 to G3. 
   Despite the prognostic power of  TNM staging system, determining the outcome for 
patients is imprecise. Tumor cells live a complex of cellular components comprising 
fibroblasts, endothelial cells, and immune cells. 
   Solid tumors are commonly infiltrated by immune cells (e.g., T and B lymphocytes, 
natural killer cells, dendritic cells, macrophages, neutrophils, eosinophils, and mast 
cells). All of them are variably scattered within the tumor and loaded with an assorted 
array of cytokines, chemokines, and inflammatory and cytotoxic mediators. This 
complex network reflects the diversity in tumor biology and tumor-host interactions. 
 Recently, data collected from large cohorts of human cancers demonstrated that the 
immune contexture of the primary tumors is an essential prognostic factor for patients' s 
disease-free and overall survival. 
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   According, recent studies argues that cancer development is strongly influenced by 
the host's immune system (5,6). This underlines the importance of the systemic and 
local immunological markers that even at the level of clinically apparent tumors should 
be evaluated in predicting the outcome. Moreover, this immune score approach is 
superior in predicting the disease outcome as compared to clinical parameters (e.g.TNM  
staging) (7). 
   In conclusion, a new classification of colorectal cancer patients could be based on the 
immune score. 
 
1.3 Cancer Stem Cell hypothesis 
   Over the last 50 years, researchers have shown that genetic and/or epigenetic events, 
that can hit any somatic cells within the tissue, induce activation or inhibition of genes 
involved in cells proliferation (oncogenes and tumor suppressor genes respectively). 
Accumulation of the above reported alterations generate cells with uncontrolled 
proliferative potential that supports the onset and growth of tumor. According to this 
“clonal evolution” hypothesis (or stochastic model) described by Nowell in 1976 (7), 
tumor is heterogeneous and every cell within the neoplasm would have the same 
capacity to proliferate extensively and thus the same potential to sustain tumour growth 
(from an experimental point of view, each colon cancer cell can be potentially able to 
recapitulate the original tumour in animal models) (8,9). 
   However, this old concept could not explain why the current anti-cancer strategies 
show limited or no effects on cancer cure. Furthermore during the development, tumor 
tissue accumulates number of alterations over years or decades, but during the self-
renewal of tissues, most of the cells are lost or eliminated within a short time and 
thereby losing all acquired mutations until then. These setbacks mostly reflect the need 
to propose a new concept of cancer that could explain the tumorigenesis. In the last few 
years, the cancer biology has radically changed the view of tumorigenesis; 
accumulating evidences have suggested that the capacity of initiating a tumour,  
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including colon carcinoma, is rather a unique feature of a small long-term population 
(residing in tissues) with stem-like properties, called “Cancer Stem Cells” (CSCs) or 
“tumour-initiating cells” CSCs have the exclusive ability to self-renewal property and 
generate a progeny of non-tumorigenic transit-amplifying cells (TAC) which give rise 
the non-tumorigenic differentiated population representing majority of tumor (bulk) 
(10,11). 
   Although solid evidence is lacking to date, CSCs are thought to derive from self-
renewing normal stem cells (SCs) that acquire epigenetic and/or genetic changes 
required for tumorigenicity, or from proliferative progenitors (PCs) that reprogram 
themselves acquiring self-renewal capacity (12). 
   CSCs, as the SCs, maintain multipotentiality giving rise to a hierarchical organization 
of cell populations that go to aberrant organogenesis. Moreover, similarly to the SCs, 
the CSCs show a low cicling rate (compared to an high proliferative potential)  that 
spares by current chemotherapy treatments which target highly proliferative cells. 
Chemoresistance, characterizing CSCs, is also due to high expression of proteins 
belonging to the family of ABC membrane transporters (which favor the cellular efflux 
of drugs), the presence of cytoprotective factors, such as telomerase activity and high 
expression of anti-apoptotic factors (Bcl-2, Bcl-xL, FLIP and PED) (13, 14). 
   Several experimental data from in vitro and in vivo experiments have shown that 
autocrine production of IL-4 by cancer cells from breast, thyroid, colon, and lung is an 
important negative regulator of apoptosis, conferring resistance to death receptors and 
chemotherapy-induced cell death (15). Moreover, it has been demonstrated that death-
resistant colon CSCs also release IL-4, which installs a death-resistant phenotype. 
   CSCs  were originally identified in acute leukemias (Bonnet et al., 1997), later in 
breast cancer and other solid tumors. The first identification of the CSCs within a solid 
tumor dates back to 2003, Al-Hajj and colleagues showed that 200 cells CD44
+
/CD24
-
/lin
low/-
 in fat pad of  NOD/SCID mice generated a breast cancer with the same 
phenotypic characteristics of original tumor (10). 
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1.4 Colorectal  Stem Cells 
   The outer layer of the colon wall (mucosa), is surrounded by an absorptive and 
secretory epithelium, folded several times to form a set ( about 14,000) of invaginations. 
Each unit presents about 2000 cells, named colonic crypt consisting of different cell 
populations: the columnar cells (also called colonocytes), abundant muco-secreting cells 
also known as globet cells, and a small fraction (about 1%) of entero-endocrine cells 
(16). 
The crypt’s cells possesses a high turnover rate, are costantly renewed about every 6 
days in normal conditions increasing their turnover after tissue damaged. Normal SCs 
reside in specialized regions defined “niches”(include fibroblasts, endothelia and 
inflammatory cells), which provide a microenvironment designed to ensure their 
survival and proliferation (17). SCs removal from the niche induces the loss of their 
properties, while niche survives (18). It has been suggested that intestinal subepithelial 
myofibroblasts (ISEMFs) play a critical role in the regulation of a correct balance 
between SCs self-renewal and differentiation, by paracrine secretion of growth factors 
and cytokines (2,19). The colorectal SCs localized near or at the bottom of the crypts 
(Figure 3) surrounded by ISEMFs, allow this high frequency of tissue renewal, dividing 
asymmetrically, to generate a cell identical to itself (SC) and a PC fated to differentiate 
in more mature cells of colonic epithelium. 
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Figure 3. Schematic representation of the intestinal crypt with hypothetical stem cells 
localization. 
 
   The asymmetrical division generates a pool of immortal SCs. This long lived stem 
cells are the source of cells with mutations and epigenetic changes. According to the 
CSC hypothesis, such mutations would be passed on to the progeny, allowing for 
progression towards cancer over time and ultimately resulting in a pool of CSCs that 
feed neoplastic formation. 
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            1.5 Identification of Colon Cancer Stem Cells 
   Recent experimental evidences suggest that a combination of several putative 
stemness markers could allow SCs isolation by cell sorting.  
   The mammalian RNA binding protein Musashi1 (Msi-1), was proposed as the first 
marker of colon SCs. Initially it was  identified in neural stem cells and involved in their 
self- renewal, was also confirmed in human colon SCs (20) located at the base of the 
crypt of small murine and human intestine. 
   Barker et al., suggest a Wnt regulation target, Lgr5 (Leucine-rich-repeat-containing 
G-protein-coupled Receptor 5) protein, as elective colorectal stem marker. It’s highly 
expressed by murine crypt base columnar cells, defined as adult stem cells, due to their 
ability to generate all epithelial lineages. Musashi1 (Msi-1), was proposed as the first 
marker of colon SCs. 
   Many research groups have proposed the surface molecule CD133 (Prominin-1) as a 
marker associated with colon cancer stemness (21). The subpopulation of CD133
+
 colon 
tumor cells show characteristics of CSCs, these cells are highly tumorigenic and 
metastatic cells (22, 23). 
   Convincing experiments recently conducted by two independent groups showed that 
only the CD133+ small fraction of cells within a colon carcinoma is capable of 
initiating tumor outgrowth . In line with these findings, it has been recently showed that 
a high number of CD133-depleted cells (2x10
6
 CD133 cells) from colon cancer 
specimens fails to generate heterotopic tumors in mouse models, whereas as few as 
2.5x10
3
 CD133+ cells are sufficient to engraft and serially reproduce the original human 
tumor phenotype Although the role of CD133 in colon CSCs  is still under debate, these 
contradictory data indicate that the use of a single marker is not always appropriate for 
the correct identification of stem cell population and that standardization of technical 
approaches for the validation of  SCs markers is necessary. 
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1.6 Colorectal CSC: clinical implications for innovative therapies 
   The discovery of CSCs in a variety of tumors has changed the view of carcinogenesis 
and therapeutic strategies. 
    A combination of 5-FU, oxaliplatin and leucovorin (referred to as FOLFOX) and a 
combination of 5-FU, oxaliplatin and irinotecan (referred to as FOLFIRI) are the current 
therapy for colon cancer patients. Actually, the therapeutic approach for colorectal 
cancer includes anti-VEGF or EGFR monoclonal antibodies which improve positive 
outcomes in patients suffering from metastatic colon cancer and severe hepatic 
dysfunction (2). However, none of these anticancer therapies is curative in most patients 
with metastatic disease due to failure to eradicate the CSCs compartment. An effective 
therapeutic approach against cancers would eliminate the pool of CSCs which are 
quiescent or slowly replicating and thus more resistant to apoptosis induced by current 
cytotoxic regiments (Figure 4). 
 
 
 
 
 
 
 
 
 
Figure 4. Resistance of CSCs to conventional therapies 
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   The CSCs hypothesis has exciting clinical implications in colorectal cancer: it could 
explain therapy failure and relapses as the result of CSCs resistance to death stimuli. 
Indeed, retaining the biological hallmarks of tissue stem cells, such as quiescence, self-
renewal ability and multidrug resistance. CSCs constitute the population intrinsically 
refractoriness to therapies developed to eradicate the rapidly dividing cells that 
constitute the majority of the non stem cell component within the tumor. 
   Future tumour diagnosis and treatments must be turned from eliminating the bulk of 
rapidly dividing but terminally differentiated components of the tumor and to be 
refocused on the minority stem cell population that fuels tumor growth.  
   It is therefore evident that a therapeutic approach to selectively target CSCs pool 
bypassing their chemoresistance could be more effective to eradicate bulk tumor. 
Recent clinical trials show that new therapeutic strategies support chemotherapy to 
obtain complete tumor eradication, they use: 
• inhibitors of survival pathways (24) 
• differentiation-inducing agents (25)  
•  immunotherapy  
 
1.7 The immunotherapy  
   The immunotherapeutical approach is based on the stimulation of the adaptive 
immune response; in fact, the discovery of tumor antigens recognized by T lymphocytes 
has stimulated the development of a variety of cancer treatment protocols aimed at 
enhancing antitumor-specific T cell responses. 
   αβ CD8+ T lymphocytes recognize CT antigens (Cancer/testis antigen also known as 
cancer/germline or shared tumor-specific antigens), which are particularly interesting 
targets because they are predicted to be expressed specifically by the tumor cells and 
not by the adjacent normal epithelial cells. 
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CT antigens are expressed in melanoma cell lines grown in embryonic stem cell media (26). 
Recent evidence show that CD133+ melanoma cells have increased expression of NY-
ESO-1 cancer/testis (CT) antigens and can be targeted by specific cytolytic T 
lymphocytes (CTLs) (27). 
   Furthemore, treatment of ovarian cancer cell lines with 5-aza-2-deoxycytidine upregulates CT 
antigen expression. (28) 
   However, the modern immunotherapy protocols have not been achieved yet positive 
clinical response. The failure of these protocols can be explained by different tumor 
escape mechanisms that have been defined in various types of malignancy. The best 
analyzed mechanism is the loss or downregulation of MHC class I antigens in tumor 
cells and it often renders tumor cells resistant to CD8 T-cell-mediated cytotoxicity  (29).   
The role of other T-cell subsets, such as γδ T and NK cells, exhibits potent cytolytic 
MHC-indipendent activity against different tumor cells in vitro, suggesting their 
potential utility as an anticancer therapy (30). 
 
 
 
            1.8 γδ T cells 
 
   T cells expressing γ and δ  T cell receptor (TCR) chains with limited usage represent 
only a small subset (2%–3%) within the total T cell population. 
Of the two major subsets of human γδ T cells, Vγ9Vδ2 T cells (referred as Vδ2 T cells) 
predominate in the peripheral blood and they constitute an abundant effector cell 
reservoir for anticancer immunotherapies (31) or anti-infectious vaccines by 
nonpeptidic (bacterial or tumor) phosphoantigens, alkylamines, and 
aminobiphosphonates recognition. 
   The other major subset, Vδ1 T cells, also called intraepithelial lymphocytes (IELs), 
comprises 70%–90% of the γδ T cells in epithelial tissues, such as in the intestine and 
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skin (32), and could respond to stress-induced MHC class I-related chain A or B (MICA 
or MICB) on epithelial and tumor cells (33). 
γδ T cells include different subsets  that are phenotypically and functionally comparable 
to those in the αβ compartment: immature (“naïve”) T cells and their mature 
counterparts. 
   Naive (TNaive , CD45RA+/CD27+) T lymphocytes are non effector cells and numerous 
in the cord blood (34). On the other hand, experienced T cells comprise “central 
memory” (TCM, CD45RA-/CD27+), “effector memory” (TEM, CD45RA-/CD27-), and 
“effector memory” cells with terminally differentiated phenotype that re-express 
CD45RA (TEMRA, CD45RA+/CD27-). TEMRA subset exercises the effector function by 
potent cytolytic activity perforin release-mediated (34-37). TCM Vδ2 cells are abundant 
in lymph nodes and lack immediate effector functions. Conversely, TEM  and TEMRA Vδ2 
effector cells are poorly represented in lymph nodes but home in peripheral tissue where 
they display immediate effector functions. (38).  
   γδ T cells have been consistently identified and isolated from tumor-infiltrating 
lymphocytes (TIL) in various types of cancer including prostate, colorectal,  breast, 
ovarian, and renal carcinoma (39-43); conversely, low percentage of γδ T cells was 
found in melanoma derived TILs. (44) 
   Vδ2 T cells have been detected in the majority of colon cancer TIL populations, and 
the response of this T-cell subpopulation to colon cancer cells suggests that a natural 
immune response mediated by these lymphocytes contributes to the 
immunosurveillance of these tumors.  
   Human Vγ9Vδ2 T cells response can be tuned by a variety of synthetic 
phosphoantigens (BrHPP) and nitrogen-containing bisphosphonates (N-BPs), such as 
zoledronate, probably via accumulation of phosphoantigens inside N-BP–treated cells 
(45) Furthemore N-BPs exhibit direct antitumor activity by both inhibiting proliferation 
and inducing apoptosis in tumor cells (46).  
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1.9 Immunotherapy using γδ T cells 
 
   In tumor immunotherapy in vivo and/or in vitro strategies are presently being 
envisaged i.e., the adoptive cell transfer of in vitro expanded γδ T cells and the in vivo 
therapeutic administration of γδ-stimulating phosphoantigens or aminobisphosphonates 
(zoledronate)  together with low dose IL-2.  Trials with aminobisphosphonates plus IL-2 
are under consideration in colon tumor and pancreatic adenocarcinoma  (47). 
   Todaro et al. demonstrated that the pretreatment of chemotherapy-sensitive or 
resistant chronic myelogenous leukemia (CML) SCs with zoledronate induces the 
activation of Vγ9Vδ2 T cells in terms of proliferation, Th1 cytokines such as IFN-γ and 
TNF-α and cytotoxic molecules release. Zoledronate-treated CSCs were more 
susceptible to Vγ9Vδ2 T cell cytotoxicity and they were almost exclusively killed by 
perforin  release rather than death receptor/ligand interactions with TRAIL and FasL. 
Results consistent with previous findings of perforin/granzyme-dominated killing 
(48,49). Furthemore, Vγ9Vδ2 T cells recognition and cytotoxicity of zoledronate-
treated CML target cells was TCR-mediated, instead NKG2D and other NK 
ligands/receptors do not appear to contribute.  
   Similar results were obtained in colon cancer (50), thus intentional activation of 
Vγ9Vδ2 T cells by zoledronate could represent a novel strategy for colorectal CSCs 
adjuvant immunotherapy. 
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Chapter II 
 
 
2.1 Introduction  
   Several experiments in mice models suggest that immune system plays an important 
role in controlling the progression of solid tumors. As, the latter are commonly 
infiltrated by immune cells (e.g. T and B lymphocytes, natural killer, mast cells, 
macrophages etc.) together with different cytochines, chemokines and cytotoxic and 
inflammatory mediators. This complex network reflects the diversity in tumor biology, 
explaining the variability of response in different patients with the same tumor. For this 
reason, in the last few years the tumor immune microenvironment has been extensively 
studied, specifically in colorectal carcinoma.   
   Galon et al considered the importance of TIL for tumor progression and correlation 
with clinical outcome. These authors assert that the type, density and location of 
immune cells within human colorectal tumors are “prognostic factors superior and 
independent then those of UICC-TNM classification”.  
   In particular they found a positive correlation between high density of cytotoxic 
(CD8+/GZMB+), memory (CD45RO+) T cells and a low incidence of colorectal tumor 
recurrence (7).  
   Furthermore, they showed an inverse correlation between immune cell density 
(immune scores) and tumor stage in fact high tumor infiltrating CD8+ / GZMB+ 
cytotoxic T cells were in situ or T1 stage tumors; in contrast, the most T4 stage  tumors 
were low T cell infiltrated. 
   The current study also demostrated that in colorectal cancer patients with 
heterogeneous densities of CD8+ T cells (intermediate outcome), the pro-inflammatory 
cytokine IL17+ could be used as interesting prognostic tool to discriminate between 
better (low level of IL17+ cells) and worse prognosis (high level of IL17+ cells). 
According to, experimental evidence have recently highlighted (revealed) high percentages of 
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CD4+ Th17 cell population in TILs from ovarian (51), melanoma, breast and colon cancer 
patients suggesting that IL 17 plays an important role in tumor microenvironment (52). 
   In colorectal, unlike melanoma (44), tumor derived-TIL it has been consistently 
identified and isolated γδ T cells. 
   Upon recognition of non-peptidic phosphoantigens, Vγ9Vδ2 T cells exert antitumor 
cytotoxic action by Perforin release. Intentional zoledronate activation of Vγ9Vδ2 T 
cells increases activity against colorectal CSCs targets and it could represent a novel 
strategy for colon cancer immunotherapy (50). 
   As demonstrated by recent evidence, there is a prevalence of infiltrating Vδ 1 T cells 
in breast and prostate cancer. In breast tumor derived-TIL it was identified a dominant 
VγVδ 1T cell population with a potent immunosuppressive function:  ability to suppress 
naive and effector T cell responses and to block the maturation and function of dendritic 
cells (44).  
   Although several studies have shown the presence of different type immune cells in 
some human cancers,. little is known regarding their generation and regulation and their 
functional role within the tumor microenvironment (53-55). 
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2.2 Aim of the study 
   As demonstrated  in recent efforts (56) tumor immune microenvironment is related 
with clinical outcomes in colorectal carcinoma. Furthermore, γδ T cells populate 
colorectal tumor TILs and constitute an important reservoir of antitumoral effectors 
MHC-unrestricted. 
   Thus, in this work we studied density as well as phenotypic and functional 
characterization of γδ (and their major subtypes) colorectal tumor-derived TIL cells 
related to tumor grading . We also investigated the effects of colorectal tumor derived 
TIL Vγ9Vδ2 T cell enhancement by phosphoantigen BrHPP or Zoledronate in terms of 
cytokines production and cytotoxic molecules content. 
   Taken together, our studies could have a prognostic value and serve as intriguing 
target for novel immunotherapeutic approaches.  
 
2.3 Materials and Methods 
 
Human colorectal samples 
 
   Colorectal cancer tissues were obtained in accordance with the ethical standards of the 
institutional committee of human experimentation from 60 patients undergoing a colon 
resection for colon adenocarcinoma in Surgical Department of Policlinico “P.Giaccone” 
Hospital, University of Palermo, (32 women and 28 men, in a range of  53 and 87 
years). Histological diagnosis was based on microscopic features of carcinoma cells 
determining the histological type and grade. 
   Peripheral blood mononuclear cells (PBMCs) (where it was possible) isolated from 
cancer patients were purified from peripheral blood by density gradient centrifugation 
using Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) and cultured in RPMI 
1640 supplemented with 10% Fetal Calf Serum (FCS), antibiotics, L-glutamine and 2-
mercaptethanol. 
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Generation of TILs 
Tumor tissue-infiltrating lymphocytes were generated from different CRC tumors (60 
patients) as described previously (44). 
   Briefly, CRC tissues were minced into small pieces followed by digestion with two 
enzymes mixture containing collagenase type IV, hyaluronidase and DNAase for 1 hr at 
37°C. After digestion, the cells were washed twice in RPMI 1640 and cultured in RPMI 
1640 containing 10% fetal calf serum (FCS) supplemented with and 50 U/ml IL-2 for 
the generation of T cells. 
   Freshly isolated PBMCs and TILs were stimulating with BrHPP 100 nM or 
Ionomycin 1mg/ml and PMA 10 mg/ml  for 5 hrs at  37°C. After  stimulation, the cells 
were washed twice in RPMI 1640 and followed for labelling by monoclonal antibodies. 
 
Flow cytometry analysis  
   The phenotipical and functional analysis of colorectal TIL γδ T cells were performed 
by FACS analysis after surface or intracellular staining with anti-human-specific mAbs 
conjugated with either different fluorochromes. These human Abs included anti-CD3, 
anti-CD4, anti-CD8, anti-CD19, anti-CD56, anti-TCR γδ, anti-Vδ2, anti-CD27 and anti-
CD45RA, anti-IL17, anti-IFN-γ, anti-TNF-α, anti-IL10, anti-perforin and anti-granzyme 
B, all purchased from Becton Dickinson, Mountain View, CA, following manufacturer's 
recommendations. Cells were analyzed with a FACScalibur flow cytometer (Becton 
Dickinson, Mountain View, CA). For every sample 10,000 viable nucleated cells were 
acquired. The results were analyzed using CellQuest software. 
 
Immunofluorescence analysis  
   Immunofluorescence stainings were performed on 5-µm-thick paraffin-embedded 
sections of human CRC tissues. For cytoplasmatic epitopes detection, samples were 
permeabilized with 0.2% TritonX-100 in PBS for 10 min, blocked with 3% BSA for 30 
min and exposed overnight at 4°C to antibodies against γδ T cell-receptor (GL3, mouse, 
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BD Biosciences Pharmingen) or isotype-matched controls at appropriate dilutions. 
Then, cells were treated with FITC anti-mouse (Molecular Probes, Inc.) plus RNase 
(200 ng/ml, Sigma) and counterstained nuclei using Toto-3 iodide (642/660, Molecular 
Probes). Confocal analysis was used to acquire fluorescence stainings. 
 
Ex vivo expansion of Vγ9 Vδ1 and Vγ9 Vδ2 T cells 
 
   To expand human Vδ1 and Vδ2 T cells, PBMCs or TILs isolated from patients with 
colorectal cancer by density gradient centrifugation using Ficoll-Hypaque (Pharmacia 
Biotech, Uppsala, Sweden) were cultured in RPMI 1640 supplemented with 10% FBS 
and antibiotics in the presence of 100 nM BrHPP or 0.5 mM zoledronate (Novartis 
Pharma) and Ionomycin 1mg/ml and PMA 10 mg/ml, added at day 0. After 48 h, 
recombinant human IL-2 (Novartis Pharma; 50 IU/ml final concentration) was added to 
the cultures, and the cells were supplemented with IL-2 every 3 days. Following 12–15 
day culture, 90% of the cells expressed the Vδ1 and Vδ2 TCR, as determined by flow 
cytometry (FACS) analysis. The cells were harvested, and purified populations of Vδ1 
and Vδ2 T cells were obtained by positive selection using magnetic microbeads 
conjugated to antihuman Vδ1 and Vδ2 mAb (mouse IgG1k, clone B6; Beckman- 
Coulter-Immunotech, Marseille, France) and immunomagnetic sorting (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Isolated cells consisted of 98% Vγ9 Vδ2 T cells, as 
determined by FACS analysis, and cell viability exceeded 95% as determined by trypan 
blue exclusion. 
         
        Statistical analysis 
 
Values of p were derived from two-tailed ANOVA tests. Values of p <0.05 were 
considered significant 
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2.4 Results 
 
 
TIL  characterization in colorectal tumors. 
 
   As suggested by Galon et al., it exists a correlation between type and density of T 
infiltrating immune cells in human colorectal tumors and clinical outcome. (57,7). 
We investigated the immune cellular profiles of lymphocytes infiltrating colon cancer  
by flow cytometry on 60 freshly resected primary tumors, using anti-CD3, anti-CD4, 
anti-CD8, anti-CD56, anti-CD16, anti-CD19 and anti-γδ TCR mAbs conjugated with 
different fluorocromes. 
 
   Flow cytometry data show that TILs consist of a heterogeneous population: the most 
represented population consisted of CD3+ T cells, both cytotoxic (CD8+) and helper 
(CD4+) T cells; also NK and B cells were represented. On the contrary, γδ T cells were 
in low percentage  in agreement with immune cellular profile where T cells expressing γ 
and δ TCR chains represent only a small subset (around 2% –3%) within the total T cell 
population (Figure 5). 
   In addition, there was significant variability in the number of colorectal TILs among 
cancer patients, in fact we found CD3+ TIL number oscillating between 5% and 80%. 
   Reason of this variability remains enigmatic but it could be related to tumor type and 
stage, general condition and age of the patient and chemio-treatment or untreatment. 
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            Figure 5.  Analysis of colorectal tumor TILs by flow-cytometric analysis 
 
 
Different location of γδ T cells 
 
Recent bibliographic data (57)  emphasize the importance of adaptive immune cell 
localization, within distinct tumor regions, to the risk of  tumor recurrence. In particular 
it has been observed that patients with high infiltration of CD8+ and CD45RO+ cells in 
the centre and invasive margin of the tumor had a lower recurrence rate (< 10%) than 
patients with low infiltration of these cells in the same regions (80%). 
We studied γδ T cell location within tumor, by immunofluorescence analysis on 
paraffin-embedded sections of human colorectal cancers. As shown in Figure 6, the 
positivity was detected  in intra-tumor and interstitial region. Actually, we don’t know 
the reasons of this different location, but further investigations may highlight their 
different response to treatments making it useful in clinical practice. 
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Figure 6. Different location of γδ T cells in the context of tumor, analysed by 
immunofluorescence analysis 
 
 
 
Positive correlation between the increase of γδ T cells population and lower 
histological grade of tumors 
 
   We investigated the possible correlation between colorectal-tumor derived TIL 
density, in particular γδ T cells, and histological grade of  human colorectal tumors.  
 To this goal, in the last 3 years we collected a group of 60 patients  Human CRC 
specimens were obtained from these patients undergoing to colorectal resection, in 
accordance with the ethical standards of the institutional committee.  
We tested the histological type and grade (G1, G2, G3)  of colorectal tumor specimens 
by histological diagnosis based on morphological microscopic features of carcinoma 
cells and conduced by Phatological Anatomy Department, policlinico “P. Giaccone”, 
Palermo. 
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   As shown in Figure 7, the most of the analyzed samples were moderately 
differentiated (G2), while 11% of specimens were characterized by a poorly 
differentiated histotype (G3).Due to the worse prognosis related to mucinous 
adenocarcinoma histotype, some authors prefer to group them with the most 
undifferentiated tumors, we found that a good percentage (16%) of samples correspond 
to this inauspicious histotype  and only a small percentage (6%) belong to soft tissue 
tumors (sarcomas) which are very rare. 
   After, we found a inverse correlation between infiltrating  γδ T cell density and tumor 
grade (Table2), because G3 tumors (associated with poor prognosis) were characterized 
by lower tumor-infiltrating T cell number than G2 and G1 samples .  
   Taken together, these data suggest that a strong intratumoral immune response is 
associated with improved clinical outcome and survival in colorectal cancer patients 
according to recent experimental evidence (57). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Figure 7.  Schematic representation of  histological characterization in cancer samples analyzed 
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2.19%sarcomi
2.91%Ca mucinoso
2.92%AdenoCa G3
3.1%AdenoCa G2
3.79%AdenoCa G1
γδ T cell density (%)tumor grade
 
 
 
 
                           
 
 
 
  
 
 
                Tab 2. Correlation between infiltrating  γδ T cell density and tumor grade.  
 
TEM and TEMRA are most represented phenotypes in infiltrating Vδ1 and Vδ2 T 
cells 
 
   In order to characterize the phenotype of different Vδ1 and Vδ2 T cell subsets we 
performed a polychromatic flow cytometry on purified and ex vivo expanded  human 
Vδ T  lymphocytes from colorectal TIL. 
   As shown in Figure 8 and Figure 9, infiltrating human Vδ1 and Vδ2 T lymphocytes 
comprise heterogeneous population of TNaive and TCM (non effector) cells together with 
2 effector memory subsets, TEM and TEMRA , that are the most represented phenotypes 
according to their intratumoral location where effector subsets of Vδ1 and Vδ2 T 
lymphocytes predominate, compared to non-effector T cells, to exert antitumor action. 
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                     Fig 8. Phenotypic characterization of  Vδ1 T cell subset by flow cytometry 
 
 
 
 
 
 
 
 
              
          Fig 9. Phenotypic characterization of  Vδ2 T cell subset by flow cytometry 
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Peripheral blood TIL
   Then we compared Vδ2 T cell subset phenotypes of freshly collected PBMCs with 
ones of colorectal TIL in each cancer patient. 
   As first step, we stained purified and ex vivo expanded human Vδ2 T  lymphocytes of 
freshly collected PBMCs (where it was possible) and bulk colorectal TIL with CD27, 
CD45RA and Vδ2 antibody.  
   FACS analysis gating on Vδ2
+
 T cell population revealed high density of TEM 
(CD45RA-/CD27-) cells in the total  Vγ9 Vδ2 T cell population isolated from PBMCs 
conversely TEMRA (CD45RA+/CD27-) phenotype was the most represented in TIL-
derived Vδ2 T cells (Figure 10) reflecting that upon recognition of specific tumor 
antigen, such as non peptidic phosphorylated metabolites, tumor infiltrating Vδ2 T cells 
differentiate into cytotoxic effector phenotypes i.e. TEMRA in order to hit cancer targets. 
 
 
                        
 
       
 
 
 
 Figure 10. Comparison of Vδ2 T cell subset phenotypes between freshly collected PBMCs and 
colorectal TILs  
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Activated γδ1 T and γδ2 T cells secrete mainly cytokines such as IFN-γ                    
and IL17. 
   It has been proposed that human γδ T cells have distinct patterns of activation and 
responses for killing tumor cells (58). These pathways include release of 
proinflammatory cytokines and proapoptotic molecules (Th1 cytokines as IFN-γ and 
TNF-α) or cell contact-dependent lysis through an NK-like or TCR-recognition.  
   To further elucidate activation and response mechanisms of stimulated tumor-
infiltrating Vδ2 (in vitro stimulation with zoledronate or BrHPP) and (in vitro 
stimulation with PMA and ionomycin) Vδ1 T cells, we assayed levels of 
proinflammatory and proapoptotic cytokines by intracellular staining for IL-10, IL-17, 
IFN-γ and TNF-α  by flow cytometry analysis. 
   We found that stimulated human colorectal  infiltrating Vδ1 and Vδ2  T lymphocytes 
are activated as detected by multiple cytokine secretion (Fig. 11-12) including the 
prototypical effector cytokine, IFN-γ  which is expressed at high levels (30% and 20% 
IFN-γ+ Vδ1 and Vδ2 T cells respectively ) as well as IL 17 (35% and 45% IL17+ Vδ1 
and Vδ2 T cells respectively ). In addition, unstimolated Vδ1 and Vδ2  T cells produce 
mainly IFN-γ  and IL 17 cytokines but with lower levels than stimulated T cells. 
As suggested by Angelini et al. (34) ex vivo data, intracellular production of IFN- γ and  
TNF-α is induced by BrHPP stimulation in V δ2 TEM h but not in V δ2  TEMRA, thus in 
this study activated Vδ2 and Vδ1T subset is realistically TEM rather than TEMRA. 
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    Figure 11. Cytokine production in activated tumor-infiltrating Vδ1 T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      
                Figure 12. Cytokine production in activated tumor-infiltrating Vδ2 T cells 
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Activated  Vγ9Vδ1 and Vγ9Vδ2 T cells induce cytotoxic Perforin/Granzyme B 
release 
 
   It is known that δ2 T cells kill tumor targets via a number of mechanisms including 
death receptor/ligand interactions with TRAIL and FasL and Perforin/Granzymes 
release. (59) 
   In order to investigate cytotoxic pathway,  TIL-derived Vγ9Vδ1 and Vγ9Vδ2 T  were 
cultured with PMA/ionomycin and phosphoantigen BrHPP or zoledronate, respectively, 
and upon stimulation, perforin and granzime B content were analysed by flow 
cytometry analysis. 
   As shown in Figures 13 and 14, Vγ9Vδ1 and Vγ9Vδ2 T express cytotoxic perforin 
and cytolytic granzime B molecules, suggesting that activated Vδ1 and Vδ2 T cells 
include effector subsets with cytotoxicity mediated by granule exocytosis-pathway. 
   Furthemore, Galon et al. evidence show  that in colon tumor a strong intratumoral 
immune response, such as high densities of CD8+ and GZMB+ cytotoxic T cells, 
protects against tumor progression and  disease relapse (disease recurrence); for these 
patients, surgery may  be curative. In this light, Perforin/Granzime B could have 
prognostic value in colorectal cancer and could indicate whether in some patients the 
surgery may be curative or not. 
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Figure 13. Perforin and Granzime B levels in activated tumor-infiltrating Vγ9Vδ1 T cells  
 
 
 
 
 
 
               
 
 
 
 
 
 
Figure 14. Perforin and Granzime B levels in activated tumor-infiltrating Vγ9Vδ2 T cells 
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2.5  Discussion  
   In colorectal cancer patients, the mean survival to 5 years is 43-47%. High mortality 
due to  inability of actual therapy to eliminate the resistant cell clone; one of the major 
impediments to this goal is the chemoresistance of CSCs. 
   Recent clinical trials show that the immunological therapy supports chemotherapy to 
obtain better results; the immunotherapeutical approach is based on the stimulation of 
the adaptive immune response.  
   The γδ T-cell receptor (TCR) lymphocytes are particularly attractive for anticancer 
immunotherapies (31) as well as anti-infectious vaccines because this unconventional 
lymphoid population, contrary to “conventional” αβ TCR T lymphocytes, exhibits MHC 
class I–independent recognition. In tumor cells, loss or downregulation of MHC class I 
antigens makes γδ T-cells an important reservoir of antitumoral effectors. 
   Vδ2 T-cells are microbial and tumoral non peptide phosphoantigens responsive, 
conversely V δ1 T-cells fail to recognize these phosphoantigens (60).  
   Thus, it is crucial to define precisely how intentional activation by synthetic 
phosphoantigens (zoledronate) may be exploited to tune Vδ2 T-cells response against 
tumor progression. Todaro et al. (50) suggests Zoledronate treatment as a novel strategy 
for colon CSCs adjuvant immunotherapy. 
γδ T cells have been consistently identified and isolated from several tumor-derived 
TIL. 
   As suggested by Galon et al. there is a close correlation between type, density, 
location of TIL and clinical outcome (57). 
   Thus, in this work the study of density as well as phenotypic and functional 
characterization of γδ colorectal-tumor-derived TIL cells could have a prognostic value 
and serve as targets for novel immunotherapeutic approaches. 
   Here we show that colorectal TILs consist of a heterogeneous population (CD3+ T, 
CD4
+
T, CD8
+
T, γδ T, B and NK cells) with lower percentage of T cells in agreement 
with immune γδ cellular profile (2%–3%) within the total T cell population. In addition, 
we found significant variability in the number of colorectal TILs among cancer patient 
group, such as CD3+ TIL number oscillating between 5% and 80%. 
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   We speculate that this variability could be correlated to tumor type and stage, general 
condition and age of the patient and chemio-treatment or untreatment raising the 
possibility that an assessment of CD3+ TIL may prove a useful prognostic tool for the 
evaluation of colorectal tumors. 
   We then found a inverse correlation between infiltrating γδ T cell number and 
histological tumor grade, because immune-cell density is lower with increasing tumor 
grade in agreement with to Galan’s study that show a strong intratumoral immune 
response (CD8+ and GZMB+ cytotoxic T cells) associated to low tumor (T) stage and 
disease-free survival. Thus, we speculate that enhancement of natural immune response 
(immunosurveillance) mediated by γδ T lymphocytes could represent a novel adjuvant 
immunotherapy  for colorectal  cancer especially in cancer patients with poor prognosis 
(high tumor grade). 
 
   In tumor immunotherapy in vivo and/or in vitro strategies are presently being 
envisaged i.e., the adoptive cell transfer of in vitro expanded γδT cells and the in vivo 
therapeutic administration of γδ-stimulating phosphoantigens or aminobisphosphonates 
(zoledronate)  together with low dose IL-2.  Trials with aminobisphosphonates plus IL-2 
are under consideration in colon tumor and pancreatic adenocarcinoma  (47) . 
   Our findings indicate a different γδ T cell localization: intra-tumor and interstitial, 
however reason of different localization remains enigmatic. 
   We focused our studies on the two major human γδ T cell subsets: γδ 1 T cells and γδ 
2 T cells. In this study we showed that, by phenotypic and functional analogy with 
differentiation stages of αβ T lymphocytes (61), human colorectal infiltrating Vδ1 and 
Vδ2 T lymphocytes comprise variable frequencies of TNaive and TCM non effector cells, 
together with 2 effector memory subsets, TEM and TEMRA, which are the most represented 
phenotypes suggesting that upon recognition of specific tumor antigen, infiltrating Vδ1 
and Vδ2 T cells differentiate into effector phenotypes to exert antitumor action. 
   In addition, we compared Vδ2 T cell subset phenotypes of freshly collected PBMCs 
with ones of colorectal TIL in each cancer patient and we found high density of TEM 
(CD45RA-/CD27-) cells in the total  Vγ9 Vδ2 T cell population isolated from PBMCs 
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conversely TEMRA (CD45RA+/CD27-) phenotype was the most represented in TIL-
derived Vδ2 T cells reflecting that upon recognition of specific tumor antigen, such as 
non peptidic phosphorylated metabolites, tumor infiltrating Vδ2 T cells differentiate 
into cytotoxic effector phenotypes (TEMRA ) in order to kill cancer targets. 
   By functional characterization we demonstrated that stimulated Vδ1 T cells (PMA and 
ionomycin) and Vδ2 T  cells (BrHPP or zoledronate) are activated as detected by high 
expression levels of prototypical effector cytokine IFN-γ and proinflammatory cytokine 
IL17 (minor IL10 and TNFα levels). Recent experimental data demonstrate that  
colorectal cancer patients with high expression of the IL17 had a poor prognosis (7, 56).  
   Finally, in this work we showed that activated TIL-derived Vδ1 and Vδ2 T effector 
subsets have cytotoxic action mediated by Perforin/Granzime B release.  
   Taken together, our data show that Th1 or cytotoxic cell markers such as    
Perforin/Granzime B or IL17 could represent not only a prognostic marker but, even 
more importantly, a novel immunotherapy target. 
   Furthermore, recent evidence dimostrate that NK-like Vδ2 TEMRA subset is highly 
active against tumoral target cells and responds to activation via CD16 (but not 
phosphoantigens) suggesting that cytokines environment is crucial in the development 
of distinct subsets rather than antigen recognition (34). An intriguing future goal could 
be to investigate  the tumor microenvironment conditions that induce selective 
differentiation into human Vδ2 TEMRA lymphocytes generating cytotoxic effectors for 
anticancer immunotherapy purposes. 
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